Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Tyler Technologies: Q4 Earnings Insights

Tyler Technologies (NYSE:TYL) reported its Q4 earnings results on Wednesday, February 14, 2024 at 04:17 PM. Here’s what…
byBenzinga Insights
February 14, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

Tyler Technologies (NYSE:TYL) reported its Q4 earnings results on Wednesday, February 14, 2024 at 04:17 PM.

Here’s what investors need to know about the announcement.

Earnings

Tyler Technologies beat estimated earnings by 1.61%, reporting an EPS of $1.89 versus an estimate of $1.86.

Revenue was up $28.71 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.15 which was followed by a 9.46% increase in the share price the next day.

Here’s a look at Tyler Technologies’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 1.99 1.89 1.69 1.75
EPS Actual 2.14 2.01 1.76 1.66
Revenue Estimate 495.85M 491.29M 471.43M 454.51M
Revenue Actual 494.68M 504.28M 471.85M 452.22M

To track all earnings releases for Tyler Technologies visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Organigram Reports 16% YoY Revenue Drop But Kicks Off Year ‘With A Bang,’ Says CEO On Hundreds Of Millions In Tobacco Giant BAT Investment

By Jelena Martinovic
February 13, 11:45 AM
Canadian cannabis producer Organigram reported a 16% decrease in net revenue for Q1 2024 due to a reduction in international revenue and medical sales. The company announced in November that it had received a CA$124.6m ($93m) strategic equity investment from BT DE Investments, a subsidiary of tobacco company British American Tobacco. Organigram shareholders approved the investment in January, and the company completed the first tranche of the investment for $41.5m. CEO Beena Goldenberg said the investment had removed a significant amount of risk from Organigram's business and enhanced its competitive advantages. The investment allows the cannabis producer to utilize its facilities, research and development capabilities, and market leadership to expand its reach within the Canadian market and beyond. Organigram's Q1 financial highlights included a drop in gross margin, an increase in selling and administrative expenses, a net loss of CA$15.8m, and positive adjusted EBITDA of CA$135,000.

BTI